$257.85
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Country

US

CEO

Mr. Joaquin Duato

IPO date

1944

Employees

138,200

ISIN

US4781601046

Key stats

Open

$255.81

Volume

8.26M

Market cap

$616.50B

Prev. close

$255.82

Impl / hst vl

-

Open interest

$0.00

$253.29

Day’s Range

$258.48

$200.91

52W Range

$274.90

Valuation

55
Valuation score
Fairly Valued
P/E
29.34
P/S
6.30
P/B
7.26
Current ratio
1.09
Debt / Equity
0.58
ROE
25.74%
Gross margin
68.38%
Income growth
5.71%
FCF growth
397.95

Sep

8

Dividends

The next payment date will be Sep 8, 2026

Div. per Share

$1.34

Div. Yield

0.52%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Buy

The average rating from top 14 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$259.30
The top 27 analysts forecasts that 12-month price may increase by 0.56%, with a low of $171.70 and a high of $299.25
$171.70
Low
$259.30
Avg
$299.25
High
Current price

Earnings

Q2 ‘26 revenue
$25.31B
Q2 ‘26 net income
$5.53B
Revenue
Net income
Previous EPS
$2.70
Estimate EPS
$2.87
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply